HA-1-specific T cell receptor therapy(Medigene)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameHA-1-specific T cell receptor therapy(Medigene)
Drug Alias NameMDG-1021MDG1021
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsPrimary MyelofibrosisMyeloproliferative DisordersMyelodysplastic Syndromes +[8] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlands
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMedigene Ag
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMedigene Ag
Active IndicationsN/A
Inactive IndicationsPrimary MyelofibrosisMyeloproliferative DisordersMyelodysplastic Syndromes +[8] 

Other Information

ATC CodeN/A
Related LinksN/A